• LLY-507: Potent SMYD2 Inhibitor for Cancer and Fibrosis Rese

  2026-07-06

  LLY-507 is a highly selective SMYD2 inhibitor with nanomolar potency, enabling precise interrogation of lysine methylation in cancer and fibrotic disease models. Its ability to block SMYD2-mediated methylation of p53 and histone substrates underpins key applications in apoptosis and cancer cell proliferation inhibition research.

• Iron Stress Reprograms Enterocyte Metabolism and Inflammatio

  2026-07-06

  Navazesh and Ji (2025) provide compelling metabolomic and transcriptional evidence that both iron deficiency and excess distinctly reshape enterocyte metabolic pathways and inflammatory gene expression. Their IPEC-J2 cell model highlights key molecular consequences of iron imbalance, offering a mechanistic foundation for translational research on intestinal health and iron-modulating interventions.

• Modeling Human Sinoatrial Node Maturation via PSC-Derived As

  2026-07-05

  This study introduces a human pluripotent stem cell-derived assembloid platform that integrates sinoatrial node and cardiac plexus organoids to model neuro-cardiac interactions essential for pacemaker maturation. By combining spatial transcriptomics and functional analyses, the work enables unprecedented insights into neuron-to-pacemaker signaling and its relevance for cardiac conduction and disease.

• Pseudouridine-Modified mRNA Vaccines: Enhanced Immune Respon

  2026-07-04

  The referenced study demonstrates that mRNA vaccines encoding SARS-CoV-2 virus-like particles, optimized with codon usage and pseudouridine modification, elicit strong antiviral immune responses in mice. These findings clarify the mechanistic value of nucleotide modification for vaccine efficacy and provide a technical foundation for future mRNA vaccine design.

• Cisplatin in Translational Oncology: Mechanism to Strategy

  2026-07-03

  This thought-leadership article explores how mechanistic insight into Cisplatin's DNA crosslinking, apoptosis induction, and oxidative stress pathways is reshaping translational cancer research. We synthesize current evidence, highlight advanced experimental strategies, compare competitive compounds, and offer actionable guidance—helping researchers future-proof oncology pipelines using APExBIO Cisplatin (CDDP, SKU A8321).

• Single-Base 5hmC Mapping Illuminates Rice Drought Epigenetic

  2026-07-03

  This study delivers the first single-base resolution map of 5-hydroxymethylcytosine (5hmC) in rice, defining its dynamic, context-specific roles in gene expression during drought adaptation. The findings reveal that 5hmC orchestrates both gene activation and repression through distinct genomic localization, providing new avenues for plant epigenetic research and crop resilience strategies.

• AICAR Phosphate (Acadesine): Advanced Workflows for B-CLL Ap

  2026-07-02

  AICAR phosphate (Acadesine) is a validated AMPK activator that enables precise, high-selectivity apoptosis induction in B-cell chronic lymphocytic leukemia (B-CLL) research. This guide distills the latest protocol enhancements, troubleshooting strategies, and mechanistic insights, translating recent discoveries on immune and metabolic regulation into actionable workflows for cancer and CNS research.

• Eltanexor (KPT-8602): Advancing XPO1 Inhibition in Cancer Mo

  2026-07-02

  Eltanexor (KPT-8602) enables researchers to precisely target nuclear export, opening new avenues for acute myeloid leukemia, CLL, lymphoma, and colorectal cancer studies. This guide details optimized workflows, troubleshooting, and the latest mechanistic innovations, allowing labs to harness Eltanexor’s robust performance with confidence.

• GW 6471: Precision PPARα Antagonist for Metabolic Research

  2026-07-01

  GW 6471 is a high-purity, small molecule PPARα antagonist used to dissect lipid metabolism and cellular signaling. By enhancing PPARα–co-repressor interactions, GW 6471 enables precise inhibition of PPARα-mediated transcription. This compound is crucial for mechanistic studies of metabolic disease and environmental toxicology.

• Indomethacin in Translational Research: Mechanisms, Models &

  2026-07-01

  This thought-leadership article explores the multifaceted utility of Indomethacin as a nonsteroidal anti-inflammatory drug (NSAID) in translational research. It integrates advanced mechanistic insights—including Cox-1/2 inhibition, PPARγ modulation, and nanoscale membrane effects—with contemporary findings on adipocyte biology, such as SEMA3E’s role in beige adipocyte differentiation. Strategic guidance is provided for experimental design, protocol optimization, and translational relevance, with a forward-looking perspective on how Indomethacin from APExBIO can accelerate discovery in inflammation, lipid metabolism, and membrane signaling studies.

• Decoding Hepatic Uptake of PEGylated Iron Oxide Nanoparticle

  2026-06-30

  This study systematically dissects how iron oxide nanoparticle size and PEG chain length dictate cellular uptake and hepatic accumulation, challenging assumptions about Kupffer cell dominance. The findings offer actionable parameters for designing nanomedicines with improved liver targeting and reduced off-target effects.

• Cisplatin in NSCLC: Mechanistic Insights & Translational Str

  2026-06-30

  Explore how mechanistic understanding of Cisplatin’s activity and emerging strategies in co-delivery systems can empower translational oncology researchers to overcome chemoresistance in non-small cell lung cancer (NSCLC). With a focus on apoptosis, DNA crosslinking, and innovative nanocarrier approaches, this article provides actionable protocol guidance and a vision for next-generation cancer research.

• a-MSH, amide: Molecular Insights for Pigmentation and Inflam

  2026-06-29

  Explore the molecular mechanisms and advanced applications of a-MSH, amide, a synthetic alpha-melanocyte-stimulating hormone amide pivotal for pigmentation regulation research. This article offers a unique, in-depth comparison to alternative methods and highlights critical protocol considerations.

• EZ Cap™ Cas9 mRNA (5-moUTP): Precision in Neurodegeneration

  2026-06-29

  EZ Cap™ Cas9 mRNA (5-moUTP) empowers researchers to perform high-fidelity CRISPR-Cas9 genome editing with minimized immune activation, even in sensitive CNS models. Its advanced capping and 5-moUTP modifications set a new standard for reproducible, efficient gene editing in neurodegenerative disease research.

• Berberine’s Protection Against Angiotensin II-Induced Atrial

  2026-06-28

  This study demonstrates that berberine inhibits NLRP3 inflammasome activation through upregulation of the SIRT6-AMPK pathway, reducing angiotensin II-induced atrial fibrosis and susceptibility to atrial fibrillation in murine models. These findings elucidate a mechanistic link between metabolic signaling, inflammation, and cardiac remodeling, informing new directions for cardiovascular and metabolic disorder research.

448 records 12/30 page Previous Next First page 上5页 1112131415 下5页 Last page